The Nuclear Regulatory Commission (NRC) recently revised 10 CFR Part 35, which covers the medical use of byproduct material. All diagnostic nuclear medicine facilities must reevaluate their procedures and protection programs to determine whether these remain in compliance and what, if any, remedial actions are necessary. At the same time, the NRC’s new risk-informed, perfor- mance-based approach focuses not on procedures but on outcomes. Specific courses of action are not prescribed, and operating policies and procedures may vary widely with modality, specific application, and size and type of institution
